Sangamo Therapeutics (SGMO) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Sangamo Therapeutics (SGMO) over the last 7 years, with Q3 2025 value amounting to -$0.11.
- Sangamo Therapeutics' EPS (Weighted Average and Diluted) fell 37500.0% to -$0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.45, marking a year-over-year increase of 4000.0%. This contributed to the annual value of -$0.49 for FY2024, which is 6714.65% up from last year.
- Per Sangamo Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.11 for Q3 2025, which was down 37500.0% from -$0.08 recorded in Q2 2025.
- In the past 5 years, Sangamo Therapeutics' EPS (Weighted Average and Diluted) ranged from a high of $0.12 in Q1 2023 and a low of -$0.66 during Q2 2023
- For the 5-year period, Sangamo Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.25, with its median value being -$0.29 (2022).
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 320000.0% in 2021, then surged by 14000.0% in 2023.
- Sangamo Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.25 in 2021, then tumbled by 34.62% to -$0.34 in 2022, then fell by 2.7% to -$0.35 in 2023, then soared by 66.44% to -$0.12 in 2024, then increased by 5.17% to -$0.11 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.11 for Q3 2025, versus -$0.08 for Q2 2025 and -$0.14 for Q1 2025.